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A human vesicular monoamine transporter cDNA has been identified by screening a human brainstem library using sequences from the rat brain 
synaptic vesicle monoamine transporter (SVMT) [(1992) Cell 70,539-551; (1992) Proc. Natl. Acad. Sci. USA 89, 10993-109971. The hSVMT shares 
92% amino acid identity with the rat sequence, but displays one less consensus ite for asparagine N-linked glycosylation and one more consensus 
site for phosphorylation by protein kinase C. The human SVMT gene maps to chromosome 10q25 using Southern blotting analysis of human/rodent 
hybrid cell lines and fluorescent in situ hybridization approaches. The cDNA, and a subclone, recognize TuqI polymorphisms that may prove useful 
to assess this gene’s involvement in neuropsychiatric disorders involving monoaminergic brain systems. 
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1. INTRODUCTION 
The vesicular monoamine transporter acts to accu- 
mulate cytosolic monoamines into synaptic vesicles, 
using the proton gradient maintained across the synap- 
tic vesicular membrane. Its proper function is a key to 
the correct activity of the monoaminergic systems that 
have been implicated in a number of human neuropsy- 
chiatric disorders [3-51. The transporter is a site of ac- 
tion of important drugs, including reserpine and tetra- 
benazine [6-81. Amphetamine and its derivatives induce 
release of vesicular monoamines by mechanisms that 
may include their uptake via the SVMT [7,9,10]. In 
addition, it has been documented to sequester monoam- 
inergic neurotoxins, such as that producing one of the 
best current experimental models of Parkinson’s dis- 
ease, MPP’ [1,11,12]. 
Recent elucidation of cDNAs encoding the rat synap- 
tic vesicular monoamine transporter [ 1,2] provides hy- 
bridization probes useful for isolation of its human cog- 
nate. We now describe the human cDNA, the unique 
features that it predicts for its encoded mRNA and 
protein, the location to which its gene maps, RFLPs 
identified by this cDNA, and estimates of the popula- 
tion frequencies of these genetic polymorphisms. These 
results provide the groundwork for examination of this 
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aminergic systems, and in human disorders of these 
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2. MATERIALS AND METHODS 
2.1. Screenrng human and rat brain cDNA libraries 
Partial cDNA hybridization probes of 1 .O and 0.8 kb corresponding 
to TM domains l-8 and 4-12, respectively, were generated by PCR 
(polymerase chain reaction) amplification of a size-selected rat ventral 
midbrain cDNA library [13], using 20nucleotide primers correspond- 
ing to previously described rat brain cDNA sequences from these 
transmembrane domains [l]. Each probe was purified by agarose gel 
electrophoresis and j2P-labeled by random priming (Prime It Kit, 
Boehringer Mannheim). Human brainstem (Stratagene) and rat ven- 
tral midbrain [13] cDNA libraries were plated and blotted onto dupli- 
cate nitrocellulose (Schleicher and Schuell) filters which were prehy- 
bridized for 4 h at 42°C in 6 x SSPE containing 29% deionized forma- 
mide, 2.5 x Denhardt’s solution, 0.1% SDS and 0.4 mg/ml herring 
sperm DNA. 1 x lo6 plaques were screened in each case using 2 x lo6 
cpm/pl of the 4-12 (rat library) or l-8 (human library) partial cDNA 
probes in the prehybridization solution at 37°C overnight. Nonspe- 
cific hybridization was elimmated with three 0.5 h washes with 
0.4 x SSPE, 0.5% SDS at 54°C. Clones detected by autoradiography 
as reproducibly positive for hybridization were isolated as Bluescript 
II SK plasmids via in vivo excision mediated by helper phage R408 
(Stratagene), and both strands were sequenced on an Applied Biosys- 
terns automated sequencer. Sequences obtained were analyzed using 
the GCG software package [14,15], with focus on the human cDNA 
clone phSVMT1 that appeared to represent he human homolog of 
previously reported rat SVMT sequences. 
Published by Elsevier Science Publishers B. V. 325 
Volume 318, number 3 FEBSLETTERS March 1993 
1 GAATTCCCGC CCGGACTGAC GGAGCCCACT GCGGTGCGGG CGTTGGCGCG 
51 GGCACGGAGG ACCCGGGCAG GCATCGCAAG CGACCCCGAG CGGAGCCCCG 
101 GAGCaGC CCTGAGCGAG CTGGCGCTGG TCCGCTGGCT GCAGGAGAGC 
151 CGCCGCTCGC GGAAGCTCAT CCTGTTCATC GTGTTCCTGG CGCTGCTGCT 
201 GGACAACATG CTGCTCACTG TCGTGGTCCC CATCATCCCA AGTTATCTGT 
251 ACAGCATTAA GCATGAGAAG AATGCTACAG AAATCCAGAC GGCCAGGCCA 
301 GTGCACACTG CCTCCATCTC AGACAGCTTC CAGAGCATCT TCTCCTATTA 
351 TGATAACTCG ACTATGGTCA CCGGGAATGC TACCAGAGAC CTGACACTTC 
401 ATCAGACCGC CACACAGCAC ATGGTGACCA ACGCGTCCGC TGTTCCTTCC 
451 GACTGTCCCA GTGAAGACAA AGACCTCCTG AATGAAAACG TGCAAGTTGG 
501 TCTGTTGTTT GCCTCGAAAG CCACCGTCCA GCTCATCACC AACCCTTTCA 
551 TAGGACTACT GACCAACAGA ATTGGCTATC CAATTCCCAT ATTTGCGGGA 
601 TTCTGCATCA TGTTTGTCTC AACAATTATG TTTGCCTTCT CCAGCAGCTA 
651 TGCCTTCCTG CTGATTGCCA GGTCGCTGCA GGGCATCGGC TCGTCCTGCT 
701 CCTCTGTGGC TGGGATGGGC ATGCTTGCCA GTGTCTACAC AGATGATGAA 
751 GAGAGAGGCA ACGTCATGGG AATCGCCTTG GGAGGCCTGG CCATGGGGGT 
801 CTTAGTGGGC CCCCCCTTCG GGAGTGTGCT CTATGAGTTT GTGGGGAAGA 
851 CGGCTCCGTT CCTGGTGCTG GCCGCCCTGG TACTCTTGGA TGGAGCTATT 
901 CAGCTCTTTG TGCTCCAGCC GTCCCGGGTG CAGCCAGAGA GTCAGAAGGG 
951 GACACCCCTA ACCACGCTGC TGAAGGACCC GTACATCCTC ATTGCTGCAG 
1001 GCTCCATCTC CTTTGCAAAC ATGGGCATCG CCATGCTGGA GCCAGCCCTG 
1051 CCCATCTGGA TGATGGAGAC CATGTGTTCC CGCAAGTGGC AGCTGGGCGT 
1101 TGCCtTCTTG CCAGCTAGTA TCTCTTATCT CATTGGAACC AATATTTTTG 
1151 GGATACTTGC ACACACAATG GGGAGGTGGC TTTGTGCTCT TCTGGGAATG 
1201 ATAATTGTTG GAGTCAGCAT TTTATGTATT CCATTTCCAA AAAACATTTA 
1251 TGGACTCATA GCTCCGAACT TTGGAGTTGG TTTTGCAAAT GGAATGGTGG 
1301 ATTCGTCAAT GATGCCTATC ATGGGCTACC TCGTAGACCT GCGGCACGTG 
1351 TCCGTCTATG GGAGTGTGTA CGCCATTGCG GATGTGGCAT TTTGTATGGG 
1401 GTATGCTATA GGTCCTTCTG CTGGTGGTGC TATTGCAAAG GCAATTGGAT 
1451 TTCCATGGCT CATGACAATT ATTGGGATAA TTGATATTCT TTTTGCCCCT 
1501 CTCTGCTTTT TTCTTCGAAG TCCACCTGCC AAAGAAGAAA AAATGGCTAT 
1551 TCTCATGGAT CACAACTGCC CTATTAAAAC AAAAATGTAC ACTCAGAATA 
1601 ATATCCAGTC ATATCCGATA GGTGAAGATG AAGAATCTGA AAGTGAm 
1651 GATGAGATCC TCAAAAATCA TCAAAGTGTT TAATTGTATA AAACAGTGTT 
1701 TCCAGTGACA CAACTCATCC AGAACTGTCT TAGTCATACC ATCCATCCCT 
1751 GGTGAAAGAG TAAAACCAAA GGTTATTATT TCAAAAAAGG AATTC 
Fig. 1. Sequence of the human SVMT cDNA. Initiation and termination codons of the open reading frame are indicated (boxed). 
labeled, and employed as a probe in Southern blot analysis of the 
NIGMS rodent somatic cell hybrid panel #2 (Cornell Institute for 
Medicine, Camden, NJ). Each human chromosome was represented 
in a separate gel lane as a Hind111 digest. 
Higher resolution mapping of the hSVMT gene was accomplished 
with chromosomal in situ hybridization. phSVMT1 was nick-trans- 
lated with biotin-14 dATP (BRL, Gaithersburg, MD), with 2 1% incor- 
poration as determined by tritium tracer incorporatton. Slides with 
chromosome spreads were made from normal male lymphocytes cul- 
tured with BrdU [16]. Fluorescence in situ was performed as described 
[17] with modifications. 20 ng&l biotinylated probe in 2 x SSCP, 50% 
formamide, 10% dextran sulfate, and 1 pg/pl salmon sperm DNA was 
denatured at 70°C for 5 min., quickly chilled on ice, placed on slides 
and hybridized at 37°C overnight. Slides were washed in 50% forma- 
midel2 x SSC at 37°C for 20 min, then twice for 5 min. Biotinylated 
probe was detected with FITC-avidin and biotmylated anti-avidin 
(Oncor, Inc.), following manufacturer’s instructions. 
2.3. Restriclion fragment length polymorphism (RFLP) analysis using 
Taql 
DNA isolated from the leukocytes of 197 unrelated individuals 
subjected to experimental protocols at the Addiction Research Center, 
NIDA, was digested with TaqI and analyzed by Southern blotting as 
described [18]. The 1.8 kb EcoRI fragment of phSVMT1 was labeled 
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as described above, and also gel-isolated and digested with TuqI to 




3.1. Ident$catinn of human and rat brain SVMT 
Human brainstem and rat ventral legmental area 
(VTA) cDNA libraries were screened with the two 
PCR-generated probes described above. From 1 x I@ 
recombinant plaques in each case, 8 and 24 hybridizing 
cDNAs were obtained from the human and rat cDNA 
libraries, respectively. Preliminary sequence analyses of 
each clone indicated that each represented a partial 
SVMT cDNA, The human cDNA clone phSVMT1 was 
found to contain an open reading frame that encoded 
a 514 amino acid protein, flanked by 105 bp of 5’- and 
145 bp of Y-untranslated sequence (Fig. 1). The rat 
cDNA clone prSVMT1 also displays an open reading 
frame that encodes a protein of 515 amino acids, fol- 
lowed by 2.0 kb of untranslated sequence. prSVMT1 is 
virtually identical to the rat brain synaptic vesicle 
monoamine transporters reported previously [ 1,2]. The 
open reading frame of the human hSVMT1 cDNA ex- 
hibits 88% nucleotide identity to the rat rSVMT se- 
quence; the predicted amino acid sequences are 92% 
identical (Fig. 2). 
3.2. Chromosomal localization of the hSVMT gene 
Somatic cell hybridization analyses revealed that 
there was 100% concordance between the presence of 
chromosome 10 and the 9,7, and 3.8 kb H;iptdIII DNA 
fragments that hybridized with the EcoRI fragment of 
phSVMT1. There was greater than 8% discordance for 
each other chromosome. 
Analysis of 119 metaphase cells demonstrated 25 cells 
(20%) that had at least one pair of hybridization signals 
that involved both chromatids of a single chromosome. 
Forty paired signals were seen; 38 (95%) were located 
near the terminal end of the long arm of a small C-group 
(chr. g-12) chromosome. To determine the specific 
chromosome and band, cells were G-banded by fluores- 
cence plus Giemsa [16] techniques, and photographs of 
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Fig. 2. Schematic representation of the hSVMT showing proposed orientation in the vesicular membrane and conservation of amino acid residues 
among vesicular modnl 1.7noamine transporters. Bold letters, residues common to human and rat SVMTs and the chromafhn granule amine 
transporter (CGAT; [l]); italic letters, residues common to hSVMT and rSVMT; hatched letters, residues common to hSVMT and CGAT: open 
letters, residues unique to hSVMT. Consensus glycosylation sites are indicated by forks. 
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Fig. 4. Ideogram of human chromosome IO showing localization of 
hSVMT cDNA to band lOq25. Each dot represents a single paired 
signal seen on banded chromosome 10 after hybridization. Signals 
plotted to the right of the ideogram were located on subbands 
lOq25.1-26.1, those to the left (bracket) were located on 1Oq25 where 
band could not be subdivided. 
banding patterns aligned with photographs of the fluo- 
rescence in situ hybridization signals to determine sub- 
band location. 26 of 30 analyzable metaphases (87%) 
were on chromosome 10, largely on band lOq25 (Fig. 
4). 
3.3. Restriction fragment length polymorphism analysis 
The Taq 1000 fragment excised from phSVMT1 re- 
vealed at least 5 different digestion patterns in TaqI- 
digested DNAs. The most striking polymorphism pro- 
duced bands of approximately 7.8 or 6 kb, termed Al 
and A2, respectively (Fig. 3). Fig. 3A demonstrates ho- 
mozygous Al individuals (lanes 3.5 and 6), Al/A2 
heterozygotes (lanes 1 and 2) and an A2 homozygote 
(lane 4). Examination of 394 chromosomes revealed an 
Al frequency of 0.71 and an A2 frequency of 0.29. 
Values in the 197 individuals surveyed showed little 
deviation from the Hardy-Weinberg equilibrium: 48% 
were Al/Al, 46% AllA2, and 6% A2lA2. Caucasians 
and blacks exhibited 0.70 and 0.77 Al frequencies, re- 
spectively, revealing no evidence of racial differences in 
allele frequencies (PO. 17, Fisher’s exact test). A second 
TaqI polymorphism also appears among the remaining 
lower molecular weight bands (lanes 24, Fig. 3B). 
Since some of these patterns appear to be rare (e.g. the 
lane 2 pattern occurs only once among the 197 individu- 
als tested), further analyses will be required to assess 
their true population frequencies. 
4. DISCUSSION 
4.1. A human cDNA contains an open reading frame 
possessing high homology to the rat brain SVMT 
The high homology of the sequence identified here 
with the rat monoamine transporter argues strongly 
that the cDNA identified here encodes a human vesicu- 
lar monoamine transporter. The open reading frame 
predicted by this cDNA encodes 5 14 amino acids, com- 
pared to 515 amino acids for the rat sequence [1,2]. The 
human and rat proteins are predicted to be 92% identi- 
cal, while no significant homology is observed between 
this human cDNA and any of the plasma membrane 
transporter cDNAs [13,19-221. Each of these features 
enhances confidence that this cDNA encodes a human 
vesicular monoamine transporter. Although the possi- 
bility that other cDNAs could encode molecules with 
similar function remains open, the cloning of the same 
rat cDNA by three different laboratories and the high 
homology of this human cDNA does provide evidence 
against the existence of an abundant, closely related 
mRNA species that encodes a different SVMT. 
4.2. Structural features and post-translational modljica- 
tions predicted for human and rat SVMTs 
The rat SVMT protein has been tentatively assigned 
the 12 transmembrane (TM) domain structure charac- 
teristic of many transporter proteins, although assign- 
ment of the exact boundaries of each TM region may 
have some uncertainty. We have employed Chou-Fas- 
man hydrophobicity analysis [23] and delineated many 
TM-cytoplasm and TM-lumen interfaces by charged 
residues. especially positively charged residues. We 
have minimized charged residues in putative TM re- 
gions and imposed a size constraint of 19-26 amino 
acids for membrane traversal (Fig. 2). The putative TM 
domains assigned in this fashion reveal remarkable con- 
servation between human and rat brain SVMTs; only 
one nonconservative change (Asn-395 (human) vs. Ile- 
396 (rat)) in TM 10 distinguishes the two. The hSVMT 
displays five negatively-charged aspartic acid residues 
in predicted TM regions, while lysine-I 38 represents the 
lone TM region positive charge. The presence of aspar- 
tic acid residues in a TM domain is a common motif 
among monoaminergic receptors and neurotransmitter 
transporters; site-directed mutagenesis tudies suggest 
that TM aspartic acids can be essential for ligand recog- 
nition and/or transport [24,25]. The 3rd and 4th SVMT 
TM domains also display serine clusters (TMs 3 and 4), 
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Fig. 3. TaqI RFLP patterns of DNAs probed with the hSVMT cDNA Taq 1000 fragment. The positions of Al and A2 bands are indicated, as 
well as sizes of lambda DNA/Hind111 molecular weight standards. 
a feature shared by the plasma membrane receptors and 
transporters in which mutagenesis has suggested that 
they may be important for ligand recognition and/or 
transport [24,25]. 
The rat/human sequence differences in extra-mem- 
branous segments lead to differences in the two pro- 
teins’ total charges. The human protein displays a net 
-1 charge and an isoelectric point of 5.68 while the net 
+2 charge of the rat protein corresponds to an isoelec- 
tric point of 6.17 [ 151. 
The large, presumably intralumenal oop positioned 
between TM domains 1 and 2 contains differences be- 
tween the human and rat amino acid sequences. The 
segment comprised of hSVMT residues 57-112 exhibits 
only 59% amino acid identity and contains 4 gaps in 
which a residue from the human SVMT sequence has 
no rat counterpart, or vice versa (Fig. 2). This lumenal 
loop region displays sites for asparagine N-linked glyco- 
sylation, based on the consensus sequence Asn-Xaa- 
(Ser,Thr) [26,27]. The human and rat SVMTs are pre- 
dicted to contain 4 such sites at (hSVMT) residues 56, 
84, 9 1 and 109. A fifth site is expected to be present at 
residue 80 in the rat sequence, occupying the same rela- 
tive position as Asp-83 in the human sequence. The fact 
that 1 less glycosylation site is available in the human 
sequence may suggest that the extent of glycosylation is 
reduced in the human protein; however, steric hin- 
drance from the neighboring glycosylated asparagine 
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residue in the rat sequence may limit the extent of post- 
translational modification at the ‘extra’ site. Study of 
the human and rat proteins will help to elucidate the 
actual extent and sites of glycosylation. 
The human and rat SVMTs also differ with respect 
to potential sites for phosphorylation by protein kinase 
C (PKC). Four sites for the consensus sequence 
(Ser,Thr)-Xaa-(Arg,Lys) [28,29] are found in putative 
intracellular segments of the human sequence (Ser-15, 
Ser- 18, Thr- 154 and Ser-28 l), while the Ser- 15 is in the 
nonconsensus Ser-Arg-His context in the rat sequence 
and may be a poorer PKC recognition site. Both rat and 
human SVMTs share a fifth potential PKC site at Thr- 
497 (Thr-Gln-Asn), 2 protein kinase A recognition sites 
at Ser-18 and Ser-417 and 2 casein kinase II sites at 
Thr-213 and Ser-511. 
4.3. RFLPpatterns and chromosomal localization of the 
hS VMT gene 
Conceivably, modifications affecting the expression 
or regulation of the SVMT gene could confer suscepti- 
bility to drug abuse or neuropsychiatric disorders. We 
therefore screened DNAs from almost 200 individuals 
for a Tag1 RFLP pattern that help to assess possible 
gene polymorphisms that could serve as markers for 
associated human disorders [18]. At least two distinct 
polymorphisms were detected (Fig. 3), allowing the 
hSVMT cDNA to provide such a potential probe. 
The chromosomal location of this gene to 10q25 
places it in the vicinity of chromosomal breaks identi- 
fied in some patients with cutis verticis gyrata with men- 
tal deficiency [30,31], although no clearly relevant disor- 
ders have been mapped to this locus to date [31]. 
4.4. Implications for the possible SVT gene family 
Several features of the present results suggest that the 
size of the family of synaptic vesicular transporters may 
well be smaller than the size of the family of sodium- 
dependent plasma membrane neurotransmitter trans- 
porter gene family [32]. Each of the positively-hybridiz- 
ing clones isolated from both the rat and human cDNA 
libraries contained a portion of the same SVMT cDNA. 
Other members of the vesicular transporter family have 
been identified on pharmacologic grounds, including a 
vesamicol-sensitive acetylcholine transporter [33]. Fu- 
ture cloning studies will identify the exact size of this 
possible gene family with more precision. 
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